EQT Private Equity to Acquire QIAGEN for ~$12.1B via All-Cash Public Takeover Offer

Shots: QIAGEN & EQT Private Equity (EQT XI fund) have signed a business combination agreement under which Crown NL Bidco B.V. will make an all-cash voluntary public takeover offer for all outstanding QIAGEN shares at €46.50/share, a 40.3% premium to the unaffected XETRA closing price of €33.15 (Jul 8, 2026) & 46.9% to the 3-mos. VWAP The transaction values QIAGEN at ~€10.8B in enterprise value (~$12.1B, incl. ~$1.1B net debt), with co-investments from Luxinva (ADIA) & CPP Investments; QIAGEN’s Supervisory & Managing Boards unanimously recommend acceptance, & EQT has committed equity & debt financing with no financing condition Closing is expected in mid-2027, subject to a minimum acceptance threshold of 50% of outstanding shares plus 1 share, EGM resolutions & regulatory clearances; QIAGEN will continue to operate under its name & brand, with its FSE & NYSE listings to be terminated in connection with the post-closing measures Ref: Business Wire  |   Image: QIAGEN  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post EQT Private Equity to Acquire QIAGEN for ~$12.1B via All-Cash Public Takeover Offer appeared first on PharmaShots.